Skip to main content
editorial
. 2018 Sep 27;10(9):543–548. doi: 10.4254/wjh.v10.i9.543

Figure 2.

Figure 2

NS5A resistance-associated substitution testing in NS5A inhibitor-experienced patients prior to retreatment with NS5A inhibitor-containing regimen. Optimized treatment strategy with NS5A resistance-associated substitutions (RAS) testing and the outcome is shown. The implementation of NS5A RAS testing is developed by decision-making based on the presence of RAS > 100X. SVR: Sustained virologic response.